Ceres Inc (CERE): Price and Financial Metrics


Ceres Inc (CERE): $25.21

0.27 (+1.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CERE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CERE Stock Price Chart Interactive Chart >

Price chart for CERE

CERE Price/Volume Stats

Current price $25.21 52-week high $46.16
Prev. close $24.94 52-week low $12.01
Day low $24.69 Volume 235,700
Day high $25.74 Avg. volume 458,914
50-day MA $30.56 Dividend yield N/A
200-day MA $31.56 Market Cap 3.73B

Ceres Inc (CERE) Company Bio


Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.


CERE Latest News Stream


Event/Time News Detail
Loading, please wait...

CERE Latest Social Stream


Loading social stream, please wait...

View Full CERE Social Stream

Latest CERE News From Around the Web

Below are the latest news stories about Cerevel Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CERE as an investment opportunity.

Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.

Brian Anderson on TipRanks | February 16, 2022

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter 2021 financial results and recent business updates on Tuesday, March 1, 2022 at 8:00 a.m. ET. To access the call, ple

Yahoo | February 16, 2022

Cerevel's Acute Anxiety Candidate Shows Encouraging Action In Healthy Volunteers

Cerevel Therapeutics Holdings Inc's (NASDAQ: CERE) 7.5 mg twice daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity in healthy volunteers compared with placebo. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The positive contro

Yahoo | February 15, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated; resulted in no serious adverse events and no treatment-related discontinuations in the trialCerevel intends to advance development of darigabat in anxiety-related disordersConference call and webcast scheduled for today

Yahoo | February 15, 2022

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in

Yahoo | January 10, 2022

Read More 'CERE' Stories Here

CERE Price Returns

1-mo -18.31%
3-mo 3.96%
6-mo -25.01%
1-year 81.11%
3-year N/A
5-year N/A
YTD -22.24%
2021 95.54%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6377 seconds.